Anyone have any news from Lauster/Jahoda teams?

[Arashi]

Do you mind explaining the difference between gene expression and Trichogenicity?

Sure. Trichogenicity just means the ability to induce a hair follicle. That's what Jahoda already achieved. Yet after expansion of the cells, genetic information was lost in the process. The cells still were able to induce a hair follice, but the resulting hair wasnt cosmetically viable: it was thin and without colour and I think it didnt even reach the surface.

[iaskdumbquestions]

No. Jahoda already solved that. It's just that the resulting hair wasnt cosmetically viable. Like Joachim just said, gene expression wasnt good enough.

Do you mind explaining the difference between gene expression and Trichogenicity?

[nameless]

No. Jahoda already solved that. It's just that the resulting hair wasnt cosmetically viable. Like Joachim just said, gene expression wasnt good enough.

Jahoda solved the trichogenicity problem partially. You and I debated this before.

The Chinese are saying they have taken up where Jahoda left off and improved on the degree of trichogenicity.

Also, have you taken a look at Kerastem? Do you recall that you said the problem with adipose derived stem cells is that they don't stay in the injected area. Well, you were right...that is the problem.
Kerastem may solve this problem and it does appear that it is producing some solid results. Plus the FDA has authorized a phase 2 study already.

[nameless]

They were just injected into mice.. the cells were from human origin. So, this is definitely different than, "just another mouse study".

I concur.

[jamesst11]

Its still mice and still wasting of time on nothing...

For now only: Replicel and Histogen!

They were just injected into mice.. the cells were from human origin. So, this is definitely different than, "just another mouse study".

[Arashi]

Arishi, two things:

1. The key problem with Jahoda's achievements are, and always have been, hair inductivity. It the Chinese have solved that problem then that should result in a breakthrough.

No. Jahoda already solved that. It's just that the resulting hair wasnt cosmetically viable. Like Joachim just said, gene expression wasnt good enough.

[FooFighter]

Its still mice and still wasting of time on nothing...

For now only: Replicel and Histogen!

[joachim]

The Chinese have mastered Jahoda's technique and are rapidly developing methods to take it to clinical trials. Here's the paper they published last month:

http://pubs.acs.org/doi/abs/10.1021/acsami.6b00202

Interestingly enough, DP cells maintained their Trichogenicity in passage 8 which is unheard of. Hair sprouted after expanding these cells 8 times. Let's see what more this year brings.

Important note: the DP cells used were human. They were just injected into mice! In before, another mouse study

like arashi said, gene expression is probably not solved yet, it's just the trichogenicity part.

my feeling is that the hanging drop method will lead nowhere. transforming iPS into DP cells is the right way to go.

also, what happened to lausters team? are you still in contact with dr. beren atac or dr. lindner?
they practically have achieved nothing so far, it's so dissapointing and frustrating. and i even think, they are not trying hard enough anymore, they probably gave up. their focus is on lab-on-a-chip only. curing hairloss or seriously growing higher amounts of hair in vitro was never their real goal i think.
furthermore, meanwhile many other companies are already working on the lab-on-a-chip thing, so that lindners team is behind others as well.
all in all, i think we can close the book about dr. lauster, dr. linder, and all others related to TU Berlin. it's over. of course they will tinker around for many more years trying meaningless stuff in their labs. in the end it's a university, and they have to do some R&D with their funds. but who cares if anything comes of it or not. let them tinker around for another decade, as long as the jobs are secured, everything is fine.

my only hope is in replicel now, as their science seems to make sense. but still there are so many unknown variables.
histogen is still dead in my opinion, but they're trying to fool investors with their combover images. we are so screwed.

[nameless]

The Chinese have mastered Jahoda's technique and are rapidly developing methods to take it to clinical trials. Here's the paper they published last month:

http://pubs.acs.org/doi/abs/10.1021/acsami.6b00202

Interestingly enough, DP cells maintained their Trichogenicity in passage 8 which is unheard of. Hair sprouted after expanding these cells 8 times. Let's see what more this year brings.

Important note: the DP cells used were human. They were just injected into mice! In before, another mouse study

What are the Chinese doing that is different from what everyone else is doing? How can they maintain trichogenicity in passage 8? What is the difference between their technique and the technique of others that allows them to do P8 and maintain trichogenicity?

[nameless]

8 passages, that's an accomplishment in itself indeed, nice to see this progress. However, key problem with Jahoda's achievements were the lack of correct cosmetic attributes like hair color and thickness. Does this article reveal anything here ?

Arishi, two things:

1. The key problem with Jahoda's achievements are, and always have been, hair inductivity. It the Chinese have solved that problem then that should result in a breakthrough.

2. You were right about the big problem with adipose derived stem cells migrating out of the injected area. Science may have found a solution to that problem. Have you checked out Kerastem?

[Arashi]

So how many 'passages' does it take before you have a working product?

passages just means dividing cells. So you take a cell, make 2 out of them, now you have 2 cells after on passage. Then you this again and you have 4 cells after 2 passages. So 8 passages just means they managed to make 256 dp cells out of just 1 dp cell and all those cells still were able to induce a hair follicle.

[allTheGoodNamesAreTaken]

The Chinese have mastered Jahoda's technique and are rapidly developing methods to take it to clinical trials. Here's the paper they published last month:

http://pubs.acs.org/doi/abs/10.1021/acsami.6b00202

Interestingly enough, DP cells maintained their Trichogenicity in passage 8 which is unheard of. Hair sprouted after expanding these cells 8 times. Let's see what more this year brings.

Important note: the DP cells used were human. They were just injected into mice! In before, another mouse study

So how many 'passages' does it take before you have a working product?

[Arashi]

The Chinese have mastered Jahoda's technique and are rapidly developing methods to take it to clinical trials. Here's the paper they published last month:

http://pubs.acs.org/doi/abs/10.1021/acsami.6b00202

Interestingly enough, DP cells maintained their Trichogenicity in passage 8 which is unheard of. Hair sprouted after expanding these cells 8 times. Let's see what more this year brings.

Important note: the DP cells used were human. They were just injected into mice! In before, another mouse study

8 passages, that's an accomplishment in itself indeed, nice to see this progress. However, key problem with Jahoda's achievements were the lack of correct cosmetic attributes like hair color and thickness. Does this article reveal anything here ?

[Desmond84]

The Chinese have mastered Jahoda's technique and are rapidly developing methods to take it to clinical trials. Here's the paper they published last month:

http://pubs.acs.org/doi/abs/10.1021/acsami.6b00202

Interestingly enough, DP cells maintained their Trichogenicity in passage 8 which is unheard of. Hair sprouted after expanding these cells 8 times. Let's see what more this year brings.

Important note: the DP cells used were human. They were just injected into mice! In before, another mouse study

[liba]

Hello guys, I have a recent paper (2/2015) from Lauster. This can help ?

A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing

Journal of Biotechnology (Impact Factor: 2.88). 02/2015; DOI: 10.1016/j.jbiotec.2015.02.002
Source: PubMed

ABSTRACT Current in vitro and animal tests for drug development are failing to emulate the systemic organ complexity of the human body and, therefore, often do not accurately predict drug toxicity, leading to high attrition rates in clinical studies (Paul et al., 2010). The phylogenetic distance between humans and laboratory animals is enormous, this affects the transferability of animal data on the efficacy of neuroprotective drugs. Therefore, many neuroprotective treatments that have shown promise in animals have not been successful when transferred to humans (Dragunow, 2008; Gibbons and Dragunow, 2010). We present a multi-organ chip capable of maintaining 3D tissues derived from various cell sources in a combined media circuit which bridges the gap in systemic and human tests. A steady state co-culture of human artificial liver microtissues and human neurospheres exposed to fluid flow over two weeks in the multi-organ chip has successfully proven its long-term performance. Daily lactate dehydrogenase activity measurements of the medium and immunofluorescence end-point staining proved the viability of the tissues and the maintenance of differentiated cellular phenotypes. Moreover, the lactate production and glucose consumption values of the tissues cultured indicated that a stable steady-state was achieved after 6 days of co-cultivation. The neurospheres remained differentiated neurons over the two-week cultivation in the multi-organ chip, proven by qPCR and immunofluorescence of the neuronal markers βIII-tubulin and microtubule-associated protein-2. Additionally, a two-week toxicity assay with a repeated substance exposure to the neurotoxic 2,5-hexanedione in two different concentrations induced high apoptosis within the neurospheres and liver microtissues, as shown by a strong increase of lactate dehydrogenase activity in the medium. The principal finding of the exposure of the co-culture to 2,5-hexanedione was that not only toxicity profiles of two different doses could be discriminated, but also that the co-cultures were more sensitive to the substance compared to respective single-tissue cultures in the multi-organ-chip. Thus, we provide here a new in vitro tool which might be utilized to predict the safety and efficacy of substances in clinical studies more accurately in the future.
Copyright © 2015. Published by Elsevier B.V.

Hmm.. i don't know exactly what to say... It is good that they are still active on something, but it is disappointing that the newest finding they are announcing is not a breakthrough of hair follicle issue they were previous onto, but something irrelevant.